JP2014504258A - 選択的プロトン共役葉酸輸送体および葉酸受容体ならびにＧＡＲＦＴａｓｅおよび／または他の葉酸代謝酵素のインヒビター化合物、ならびにその使用方法 - Google Patents
選択的プロトン共役葉酸輸送体および葉酸受容体ならびにＧＡＲＦＴａｓｅおよび／または他の葉酸代謝酵素のインヒビター化合物、ならびにその使用方法 Download PDFInfo
- Publication number
- JP2014504258A JP2014504258A JP2013533912A JP2013533912A JP2014504258A JP 2014504258 A JP2014504258 A JP 2014504258A JP 2013533912 A JP2013533912 A JP 2013533912A JP 2013533912 A JP2013533912 A JP 2013533912A JP 2014504258 A JP2014504258 A JP 2014504258A
- Authority
- JP
- Japan
- Prior art keywords
- bond
- carbon atoms
- carbonyl
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 402
- 238000000034 method Methods 0.000 title claims abstract description 110
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 12
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 12
- 239000003112 inhibitor Substances 0.000 title claims abstract description 11
- 102000006815 folate receptor Human genes 0.000 title claims description 54
- 108020005243 folate receptor Proteins 0.000 title claims description 54
- 102000056797 Proton-Coupled Folate Transporter Human genes 0.000 title abstract description 7
- 108091007566 SLC46A1 Proteins 0.000 title abstract description 7
- 210000004027 cell Anatomy 0.000 claims abstract description 73
- 150000003839 salts Chemical class 0.000 claims abstract description 52
- 239000000651 prodrug Substances 0.000 claims abstract description 49
- 229940002612 prodrug Drugs 0.000 claims abstract description 49
- 239000012453 solvate Substances 0.000 claims abstract description 49
- -1 cyclic pyrimidine compounds Chemical class 0.000 claims abstract description 43
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 39
- 230000008685 targeting Effects 0.000 claims abstract description 25
- 201000011510 cancer Diseases 0.000 claims abstract description 22
- 150000004677 hydrates Chemical class 0.000 claims abstract description 22
- 210000002540 macrophage Anatomy 0.000 claims abstract description 21
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 10
- 102000005962 receptors Human genes 0.000 claims abstract description 9
- 108020003175 receptors Proteins 0.000 claims abstract description 9
- 102000037909 Folate transporters Human genes 0.000 claims abstract description 6
- 108091006783 Folate transporters Proteins 0.000 claims abstract description 6
- 230000037361 pathway Effects 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 449
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 273
- 125000000217 alkyl group Chemical group 0.000 claims description 209
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 207
- 229910052739 hydrogen Inorganic materials 0.000 claims description 111
- 239000001257 hydrogen Substances 0.000 claims description 108
- 229910052799 carbon Inorganic materials 0.000 claims description 95
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 83
- 150000001721 carbon Chemical group 0.000 claims description 82
- 239000008194 pharmaceutical composition Substances 0.000 claims description 47
- 229910052717 sulfur Inorganic materials 0.000 claims description 43
- 125000000623 heterocyclic group Chemical group 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 36
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 35
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 35
- 229910052760 oxygen Inorganic materials 0.000 claims description 35
- 239000001301 oxygen Substances 0.000 claims description 35
- 239000011593 sulfur Substances 0.000 claims description 35
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 34
- 230000003287 optical effect Effects 0.000 claims description 28
- 125000004429 atom Chemical group 0.000 claims description 26
- 150000002431 hydrogen Chemical group 0.000 claims description 24
- QAPXLUZMMFIIBI-UHFFFAOYSA-N 1,1,3,3-tetrafluoropropan-2-one Chemical compound FC(F)C(=O)C(F)F QAPXLUZMMFIIBI-UHFFFAOYSA-N 0.000 claims description 22
- HKIPCXRNASWFRU-UHFFFAOYSA-N 1,3-difluoropropan-2-one Chemical compound FCC(=O)CF HKIPCXRNASWFRU-UHFFFAOYSA-N 0.000 claims description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 22
- 102000002114 Reduced Folate Carrier Human genes 0.000 claims description 22
- 108050009454 Reduced Folate Carrier Proteins 0.000 claims description 22
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 22
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 claims description 22
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 22
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 19
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 18
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 18
- 101001116987 Homo sapiens Proton-coupled folate transporter Proteins 0.000 claims description 16
- 102000046517 human SLC46A1 Human genes 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 9
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 230000001066 destructive effect Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000002934 lysing effect Effects 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 102100035139 Folate receptor alpha Human genes 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims 1
- 230000007524 negative regulation of DNA replication Effects 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract description 49
- 235000019152 folic acid Nutrition 0.000 abstract description 35
- 239000011724 folic acid Substances 0.000 abstract description 34
- 229940014144 folate Drugs 0.000 abstract description 19
- 101000606741 Homo sapiens Phosphoribosylglycinamide formyltransferase Proteins 0.000 abstract description 10
- 102100039654 Phosphoribosylglycinamide formyltransferase Human genes 0.000 abstract description 10
- 102000010451 Folate receptor alpha Human genes 0.000 abstract description 4
- 108050001931 Folate receptor alpha Proteins 0.000 abstract description 4
- 102000010449 Folate receptor beta Human genes 0.000 abstract description 2
- 108050001930 Folate receptor beta Proteins 0.000 abstract description 2
- 150000002224 folic acids Chemical class 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 55
- 239000000843 powder Substances 0.000 description 51
- 238000004809 thin layer chromatography Methods 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 39
- 239000000243 solution Substances 0.000 description 37
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 33
- 238000002844 melting Methods 0.000 description 31
- 230000008018 melting Effects 0.000 description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 30
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 238000007429 general method Methods 0.000 description 17
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 229960000304 folic acid Drugs 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 125000003118 aryl group Chemical group 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 101000727836 Homo sapiens Reduced folate transporter Proteins 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 230000003432 anti-folate effect Effects 0.000 description 12
- 229940127074 antifolate Drugs 0.000 description 12
- 239000004052 folic acid antagonist Substances 0.000 description 12
- 229960005079 pemetrexed Drugs 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 102000053179 human SLC19A1 Human genes 0.000 description 11
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 10
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 10
- 230000008034 disappearance Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000003419 tautomerization reaction Methods 0.000 description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
- WSEQLMQNPBNMSL-FJXQXJEOSA-N diethyl (2s)-2-aminopentanedioate;hydron;chloride Chemical compound Cl.CCOC(=O)CC[C@H](N)C(=O)OCC WSEQLMQNPBNMSL-FJXQXJEOSA-N 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 229960000485 methotrexate Drugs 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 239000002253 acid Substances 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- GPIQOFWTZXXOOV-UHFFFAOYSA-N 2-chloro-4,6-dimethoxy-1,3,5-triazine Chemical compound COC1=NC(Cl)=NC(OC)=N1 GPIQOFWTZXXOOV-UHFFFAOYSA-N 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 6
- 108010022394 Threonine synthase Proteins 0.000 description 6
- 125000002877 alkyl aryl group Chemical group 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- IOQWCZKWYJSIPY-UHFFFAOYSA-N 2-aminopyrrolo[2,3-d]pyrimidin-4-one Chemical class NC1=NC(=O)C2=CC=NC2=N1 IOQWCZKWYJSIPY-UHFFFAOYSA-N 0.000 description 4
- VGUWZCUCNQXGBU-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-5-nitro-1h-indole Chemical compound C1CN(C)CCN1CC1=CNC2=CC=C([N+]([O-])=O)C=C12 VGUWZCUCNQXGBU-UHFFFAOYSA-N 0.000 description 4
- KLMZXANYZIQMCJ-UHFFFAOYSA-N 4-[3-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)propyl]thiophene-2-carboxylic acid Chemical compound C=1OC2=NC(N)=NC(N)=C2C=1CCCC1=CSC(C(O)=O)=C1 KLMZXANYZIQMCJ-UHFFFAOYSA-N 0.000 description 4
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 102000005497 Thymidylate Synthase Human genes 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- SWELIMKTDYHAOY-UHFFFAOYSA-N 2,4-diamino-6-hydroxypyrimidine Chemical compound NC1=CC(=O)N=C(N)N1 SWELIMKTDYHAOY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 3
- SPCMQFLNOVTUBM-UHFFFAOYSA-N [7-(dimethylazaniumyl)-10h-phenothiazin-3-yl]-dimethylazanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=C([NH+](C)C)C=C2SC3=CC([NH+](C)C)=CC=C3NC2=C1 SPCMQFLNOVTUBM-UHFFFAOYSA-N 0.000 description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 125000003435 aroyl group Chemical group 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- WDXARKSUQRZCBL-KRWDZBQOSA-N diethyl (2s)-2-[[3-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]thiophene-2-carbonyl]amino]pentanedioate Chemical compound S1C=CC(C#CCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1C(=O)N[C@@H](CCC(=O)OCC)C(=O)OCC WDXARKSUQRZCBL-KRWDZBQOSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 238000004896 high resolution mass spectrometry Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- WWRYNHDSHKCBOG-UHFFFAOYSA-N methyl 4-(4-hydroxybutyl)thiophene-2-carboxylate Chemical compound COC(=O)C1=CC(CCCCO)=CS1 WWRYNHDSHKCBOG-UHFFFAOYSA-N 0.000 description 3
- HPZXLAIWCQLSAR-UHFFFAOYSA-N methyl 4-bromothiophene-2-carboxylate Chemical compound COC(=O)C1=CC(Br)=CS1 HPZXLAIWCQLSAR-UHFFFAOYSA-N 0.000 description 3
- VKSTXKPRPAKVQS-UHFFFAOYSA-N methyl 5-(4-hydroxybutyl)thiophene-3-carboxylate Chemical compound COC(=O)C1=CSC(CCCCO)=C1 VKSTXKPRPAKVQS-UHFFFAOYSA-N 0.000 description 3
- VFWZOBQPAHYSDL-UHFFFAOYSA-N methyl 5-bromothiophene-3-carboxylate Chemical compound COC(=O)C1=CSC(Br)=C1 VFWZOBQPAHYSDL-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 2
- FOVLANIFKYUIDN-UHFFFAOYSA-N 4-(4-methoxycarbonylthiophen-2-yl)butanoic acid Chemical compound COC(=O)C1=CSC(CCCC(O)=O)=C1 FOVLANIFKYUIDN-UHFFFAOYSA-N 0.000 description 2
- JEKUICGHVDPYFL-UHFFFAOYSA-N 4-(5-methoxycarbonylthiophen-3-yl)butanoic acid Chemical compound COC(=O)C1=CC(CCCC(O)=O)=CS1 JEKUICGHVDPYFL-UHFFFAOYSA-N 0.000 description 2
- HMULUUWYAACBES-UHFFFAOYSA-N 4-[3-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophene-2-carboxylic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCC1=CSC(C(O)=O)=C1 HMULUUWYAACBES-UHFFFAOYSA-N 0.000 description 2
- RDXWSUCRIWBETJ-UHFFFAOYSA-N 5-[3-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophene-3-carboxylic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCC1=CC(C(O)=O)=CS1 RDXWSUCRIWBETJ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 2
- NVHRBQOZEMFKLD-CUYJMHBOSA-N BGC 945 Chemical compound C#CCN([C@@H]1C=2C=C3C(=O)N=C(NC3=CC=2CC1)CO)C1=CC=C(C(=O)N[C@@H](CCC(=O)N[C@H](CCC(O)=O)C(O)=O)C(O)=O)C=C1 NVHRBQOZEMFKLD-CUYJMHBOSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 229960005556 ONX-0801 Drugs 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- RJKJMFUURMQPLW-KRWDZBQOSA-N diethyl (2s)-2-[[2-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]thiophene-3-carbonyl]amino]pentanedioate Chemical compound C1=CSC(C#CCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1C(=O)N[C@@H](CCC(=O)OCC)C(=O)OCC RJKJMFUURMQPLW-KRWDZBQOSA-N 0.000 description 2
- QTQMRQZGRRCGMU-KRWDZBQOSA-N diethyl (2s)-2-[[2-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-3-carbonyl]amino]pentanedioate Chemical compound C1=CSC(CCCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1C(=O)N[C@@H](CCC(=O)OCC)C(=O)OCC QTQMRQZGRRCGMU-KRWDZBQOSA-N 0.000 description 2
- QBRQPIAIRZMJMR-KRWDZBQOSA-N diethyl (2s)-2-[[3-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]amino]pentanedioate Chemical compound S1C=CC(CCCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1C(=O)N[C@@H](CCC(=O)OCC)C(=O)OCC QBRQPIAIRZMJMR-KRWDZBQOSA-N 0.000 description 2
- QWWKAABOLNDKQQ-INIZCTEOSA-N diethyl (2s)-2-[[4-[3-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophene-2-carbonyl]amino]pentanedioate Chemical compound S1C(C(=O)N[C@@H](CCC(=O)OCC)C(=O)OCC)=CC(CCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1 QWWKAABOLNDKQQ-INIZCTEOSA-N 0.000 description 2
- FGCAXDJXVARMPU-KRWDZBQOSA-N diethyl (2s)-2-[[4-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]thiophene-2-carbonyl]amino]pentanedioate Chemical compound S1C(C(=O)N[C@@H](CCC(=O)OCC)C(=O)OCC)=CC(C#CCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1 FGCAXDJXVARMPU-KRWDZBQOSA-N 0.000 description 2
- HGSOWRIHHIESHW-SFHVURJKSA-N diethyl (2s)-2-[[4-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]thiophene-3-carbonyl]amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CSC=C1C#CCCC(N1)=CC2=C1N=C(N)NC2=O HGSOWRIHHIESHW-SFHVURJKSA-N 0.000 description 2
- KOEHUAJTTOCITN-KRWDZBQOSA-N diethyl (2s)-2-[[4-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]amino]pentanedioate Chemical compound S1C(C(=O)N[C@@H](CCC(=O)OCC)C(=O)OCC)=CC(CCCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1 KOEHUAJTTOCITN-KRWDZBQOSA-N 0.000 description 2
- BUWFXASJDLBNPO-SFHVURJKSA-N diethyl (2s)-2-[[4-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-3-carbonyl]amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CSC=C1CCCCC(N1)=CC2=C1N=C(N)NC2=O BUWFXASJDLBNPO-SFHVURJKSA-N 0.000 description 2
- OEJDBCVSVLUOIO-KRWDZBQOSA-N diethyl (2s)-2-[[5-[3-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophene-3-carbonyl]amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CSC(CCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1 OEJDBCVSVLUOIO-KRWDZBQOSA-N 0.000 description 2
- CKYCJNUONVSVDW-IBGZPJMESA-N diethyl (2s)-2-[[5-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]pyridine-2-carbonyl]amino]pentanedioate Chemical compound C1=NC(C(=O)N[C@@H](CCC(=O)OCC)C(=O)OCC)=CC=C1C#CCCC(N1)=CC2=C1N=C(N)NC2=O CKYCJNUONVSVDW-IBGZPJMESA-N 0.000 description 2
- TVLPQMLVDOMTGF-SFHVURJKSA-N diethyl (2s)-2-[[5-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]thiophene-3-carbonyl]amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CSC(C#CCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1 TVLPQMLVDOMTGF-SFHVURJKSA-N 0.000 description 2
- DTRBJESAEHZRKH-IBGZPJMESA-N diethyl (2s)-2-[[5-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]pyridine-2-carbonyl]amino]pentanedioate Chemical compound C1=NC(C(=O)N[C@@H](CCC(=O)OCC)C(=O)OCC)=CC=C1CCCCC(N1)=CC2=C1N=C(N)NC2=O DTRBJESAEHZRKH-IBGZPJMESA-N 0.000 description 2
- UXFQTLXBFPONHH-SFHVURJKSA-N diethyl (2s)-2-[[5-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-3-carbonyl]amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CSC(CCCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1 UXFQTLXBFPONHH-SFHVURJKSA-N 0.000 description 2
- RDSUNOBUQYYHRW-IBGZPJMESA-N diethyl (2s)-2-[[6-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]pyridine-2-carbonyl]amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CC=CC(C#CCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=N1 RDSUNOBUQYYHRW-IBGZPJMESA-N 0.000 description 2
- MKYKUJWUUALQNK-IBGZPJMESA-N diethyl (2s)-2-[[6-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]pyridine-3-carbonyl]amino]pentanedioate Chemical compound N1=CC(C(=O)N[C@@H](CCC(=O)OCC)C(=O)OCC)=CC=C1C#CCCC(N1)=CC2=C1N=C(N)NC2=O MKYKUJWUUALQNK-IBGZPJMESA-N 0.000 description 2
- IZHNUCZSFXRIPS-IBGZPJMESA-N diethyl (2s)-2-[[6-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]pyridine-2-carbonyl]amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CC=CC(CCCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=N1 IZHNUCZSFXRIPS-IBGZPJMESA-N 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 2
- 235000007635 levomefolic acid Nutrition 0.000 description 2
- 239000011578 levomefolic acid Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QUTWBLLBOJHBST-UHFFFAOYSA-N methyl 4-(4-hydroxybut-1-ynyl)thiophene-2-carboxylate Chemical compound COC(=O)C1=CC(C#CCCO)=CS1 QUTWBLLBOJHBST-UHFFFAOYSA-N 0.000 description 2
- RGFQDJSXVQPSOG-UHFFFAOYSA-N methyl 4-[3-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC(CCCC=2C3=C(N)N=C(N)N=C3OC=2)=C1 RGFQDJSXVQPSOG-UHFFFAOYSA-N 0.000 description 2
- FDYPHKREEZGWCB-UHFFFAOYSA-N methyl 5-(4-hydroxybut-1-ynyl)thiophene-3-carboxylate Chemical compound COC(=O)C1=CSC(C#CCCO)=C1 FDYPHKREEZGWCB-UHFFFAOYSA-N 0.000 description 2
- DJLORZXYURUBBP-UHFFFAOYSA-N methyl 5-[3-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)propyl]thiophene-3-carboxylate Chemical compound COC(=O)C1=CSC(CCCC=2C3=C(N)N=C(N)N=C3OC=2)=C1 DJLORZXYURUBBP-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229960004432 raltitrexed Drugs 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 229930192474 thiophene Chemical group 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DJBPYPCKXOFYII-USZFVNFHSA-N (2r)-2-[[(4s)-4-carboxy-4-[[4-[[(6s)-2-methyl-4-oxo-1,6,7,8-tetrahydrocyclopenta[g]quinazolin-6-yl]-prop-2-ynylamino]benzoyl]amino]butanoyl]amino]pentanedioic acid Chemical compound C#CCN([C@@H]1C2=CC3=C(O)N=C(N=C3C=C2CC1)C)C1=CC=C(C(=O)N[C@@H](CCC(=O)N[C@H](CCC(O)=O)C(O)=O)C(O)=O)C=C1 DJBPYPCKXOFYII-USZFVNFHSA-N 0.000 description 1
- VMBXCLLYKQHRLU-ZDUSSCGKSA-N (2s)-2-[[2-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]thiophene-3-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCC#CC=1SC=CC=1C(=O)N[C@@H](CCC(O)=O)C(O)=O VMBXCLLYKQHRLU-ZDUSSCGKSA-N 0.000 description 1
- KPLUEWVRYVJTJJ-ZDUSSCGKSA-N (2s)-2-[[2-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-3-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCCC=1SC=CC=1C(=O)N[C@@H](CCC(O)=O)C(O)=O KPLUEWVRYVJTJJ-ZDUSSCGKSA-N 0.000 description 1
- ZTCHLSUWWVOVDG-ZDUSSCGKSA-N (2s)-2-[[3-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]thiophene-2-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCC#CC=1C=CSC=1C(=O)N[C@@H](CCC(O)=O)C(O)=O ZTCHLSUWWVOVDG-ZDUSSCGKSA-N 0.000 description 1
- WYAXAXJXMQJZSJ-ZDUSSCGKSA-N (2s)-2-[[3-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCCC=1C=CSC=1C(=O)N[C@@H](CCC(O)=O)C(O)=O WYAXAXJXMQJZSJ-ZDUSSCGKSA-N 0.000 description 1
- UNSSSMUKJOLMJV-LBPRGKRZSA-N (2s)-2-[[4-[3-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophene-2-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCC1=CSC(C(=O)N[C@@H](CCC(O)=O)C(O)=O)=C1 UNSSSMUKJOLMJV-LBPRGKRZSA-N 0.000 description 1
- ZWPIWYDLNREGOJ-ZDUSSCGKSA-N (2s)-2-[[4-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]thiophene-2-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCC#CC1=CSC(C(=O)N[C@@H](CCC(O)=O)C(O)=O)=C1 ZWPIWYDLNREGOJ-ZDUSSCGKSA-N 0.000 description 1
- QPZJOZYJBPCCET-AWEZNQCLSA-N (2s)-2-[[4-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]thiophene-3-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCC#CC1=CSC=C1C(=O)N[C@@H](CCC(O)=O)C(O)=O QPZJOZYJBPCCET-AWEZNQCLSA-N 0.000 description 1
- VMGGIKVXYOZFJO-ZDUSSCGKSA-N (2s)-2-[[4-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCCC1=CSC(C(=O)N[C@@H](CCC(O)=O)C(O)=O)=C1 VMGGIKVXYOZFJO-ZDUSSCGKSA-N 0.000 description 1
- MHEHRQRNAUDDGW-AWEZNQCLSA-N (2s)-2-[[4-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-3-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCCC1=CSC=C1C(=O)N[C@@H](CCC(O)=O)C(O)=O MHEHRQRNAUDDGW-AWEZNQCLSA-N 0.000 description 1
- RMEHPWHLFJJYTB-ZDUSSCGKSA-N (2s)-2-[[5-[3-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophene-3-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCC1=CC(C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CS1 RMEHPWHLFJJYTB-ZDUSSCGKSA-N 0.000 description 1
- VKYMIASYZYDIRX-HNNXBMFYSA-N (2s)-2-[[5-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]pyridine-2-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCC#CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C1 VKYMIASYZYDIRX-HNNXBMFYSA-N 0.000 description 1
- STSPSPASIJYALB-AWEZNQCLSA-N (2s)-2-[[5-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]thiophene-3-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCC#CC1=CC(C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CS1 STSPSPASIJYALB-AWEZNQCLSA-N 0.000 description 1
- FSOJIOKMUXQEMI-HNNXBMFYSA-N (2s)-2-[[5-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]pyridine-2-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C1 FSOJIOKMUXQEMI-HNNXBMFYSA-N 0.000 description 1
- JBVKQLSCSCXKDY-AWEZNQCLSA-N (2s)-2-[[5-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-3-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCCC1=CC(C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CS1 JBVKQLSCSCXKDY-AWEZNQCLSA-N 0.000 description 1
- XOTHLEQQKQOJFM-HNNXBMFYSA-N (2s)-2-[[6-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]pyridine-2-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCC#CC1=CC=CC(C(=O)N[C@@H](CCC(O)=O)C(O)=O)=N1 XOTHLEQQKQOJFM-HNNXBMFYSA-N 0.000 description 1
- GNWFLMUDKOYTGP-HNNXBMFYSA-N (2s)-2-[[6-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)but-1-ynyl]pyridine-3-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCC#CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=N1 GNWFLMUDKOYTGP-HNNXBMFYSA-N 0.000 description 1
- MOXHYHJYCFVSLZ-HNNXBMFYSA-N (2s)-2-[[6-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]pyridine-2-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCCC1=CC=CC(C(=O)N[C@@H](CCC(O)=O)C(O)=O)=N1 MOXHYHJYCFVSLZ-HNNXBMFYSA-N 0.000 description 1
- OUMBMSSXXWAJDS-HNNXBMFYSA-N (2s)-2-[[6-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]pyridine-3-carbonyl]amino]pentanedioic acid Chemical compound C=1C=2C(=O)NC(N)=NC=2NC=1CCCCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=N1 OUMBMSSXXWAJDS-HNNXBMFYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- TZZDVPMABRWKIZ-MFTLXVFQSA-N 3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC=1C=C2CC[C@@H]([C@@H](C2=CC=1)C1=CC=C(C=C1)N1CCC(CC1)CN1CCN(CC1)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C1=CC=CC=C1 TZZDVPMABRWKIZ-MFTLXVFQSA-N 0.000 description 1
- BCCZFOXKKDTUTF-UHFFFAOYSA-N 5h-cyclopenta[g]quinazoline Chemical compound C1=NC=C2CC3=CC=CC3=CC2=N1 BCCZFOXKKDTUTF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NOTGFIUVDGNKRI-UUOKFMHZSA-N AICA ribonucleotide Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 NOTGFIUVDGNKRI-UUOKFMHZSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000046326 Alitta Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 0 CBC=C([C@@]1*(*)C(*)*C(*2)=CC3=C2N=C(*)NC3=O)C=CC1C(N[C@@](CCC(O)=O)C(O)=O)=O Chemical compound CBC=C([C@@]1*(*)C(*)*C(*2)=CC3=C2N=C(*)NC3=O)C=CC1C(N[C@@](CCC(O)=O)C(O)=O)=O 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RAPBNVDSDCTNRC-UHFFFAOYSA-N Chlorobenzilate Chemical compound C=1C=C(Cl)C=CC=1C(O)(C(=O)OCC)C1=CC=C(Cl)C=C1 RAPBNVDSDCTNRC-UHFFFAOYSA-N 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100035143 Folate receptor gamma Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101001023202 Homo sapiens Folate receptor gamma Proteins 0.000 description 1
- 108010072462 Hydroxymethyl and Formyl Transferases Proteins 0.000 description 1
- 102000006933 Hydroxymethyl and Formyl Transferases Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000015841 Major facilitator superfamily Human genes 0.000 description 1
- 108050004064 Major facilitator superfamily Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
- 102100029753 Reduced folate transporter Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000037842 advanced-stage tumor Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005325 aryloxy aryl group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- OTJZCIYGRUNXTP-UHFFFAOYSA-N but-3-yn-1-ol Chemical compound OCCC#C OTJZCIYGRUNXTP-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HSCOOHIOEWJSKN-JTQLQIEISA-N diethyl (2s)-2-[(2-bromothiophene-3-carbonyl)amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C=1C=CSC=1Br HSCOOHIOEWJSKN-JTQLQIEISA-N 0.000 description 1
- WFUJOWAXWDTMDU-JTQLQIEISA-N diethyl (2s)-2-[(3-bromothiophene-2-carbonyl)amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C=1SC=CC=1Br WFUJOWAXWDTMDU-JTQLQIEISA-N 0.000 description 1
- HJEKXOOBMOQWFU-JTQLQIEISA-N diethyl (2s)-2-[(4-bromothiophene-2-carbonyl)amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CC(Br)=CS1 HJEKXOOBMOQWFU-JTQLQIEISA-N 0.000 description 1
- WIXUSVOLOPMORP-NSHDSACASA-N diethyl (2s)-2-[(4-bromothiophene-3-carbonyl)amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CSC=C1Br WIXUSVOLOPMORP-NSHDSACASA-N 0.000 description 1
- LNHDGMFTGDIPSM-JTQLQIEISA-N diethyl (2s)-2-[(5-bromothiophene-3-carbonyl)amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CSC(Br)=C1 LNHDGMFTGDIPSM-JTQLQIEISA-N 0.000 description 1
- VQZBDOSPDJUZSI-IBGZPJMESA-N diethyl (2s)-2-[[6-[4-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)butyl]pyridine-3-carbonyl]amino]pentanedioate Chemical compound N1=CC(C(=O)N[C@@H](CCC(=O)OCC)C(=O)OCC)=CC=C1CCCCC(N1)=CC2=C1N=C(N)NC2=O VQZBDOSPDJUZSI-IBGZPJMESA-N 0.000 description 1
- HERPVHLYIHBEFW-ZETCQYMHSA-N diethyl (2s)-2-aminopentanedioate Chemical compound CCOC(=O)CC[C@H](N)C(=O)OCC HERPVHLYIHBEFW-ZETCQYMHSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- BFXLJWUGRPGMFU-UHFFFAOYSA-N dipropoxyphosphinothioyl n,n-diethylcarbamodithioate;sulfane Chemical compound S.CCCOP(=S)(OCCC)SC(=S)N(CC)CC BFXLJWUGRPGMFU-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- RNNFQNYQUXVGDB-UHFFFAOYSA-N furo[2,3-d]pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=C2C=COC2=N1 RNNFQNYQUXVGDB-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- GTMMLRWUGFHPLB-UHFFFAOYSA-N methyl 4-[3-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC(CCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1 GTMMLRWUGFHPLB-UHFFFAOYSA-N 0.000 description 1
- RJKXNIMKMAMOBT-UHFFFAOYSA-N methyl 5-[3-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophene-3-carboxylate Chemical compound COC(=O)C1=CSC(CCCC=2NC3=C(C(NC(N)=N3)=O)C=2)=C1 RJKXNIMKMAMOBT-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108010037379 ribosome releasing factor Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/902,310 US20110082158A1 (en) | 2008-10-01 | 2010-10-12 | Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same |
| US12/902,310 | 2010-10-12 | ||
| PCT/US2011/055584 WO2012051105A2 (en) | 2010-10-12 | 2011-10-10 | Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014504258A true JP2014504258A (ja) | 2014-02-20 |
| JP2014504258A5 JP2014504258A5 (enExample) | 2014-11-27 |
Family
ID=45938910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013533912A Pending JP2014504258A (ja) | 2010-10-12 | 2011-10-10 | 選択的プロトン共役葉酸輸送体および葉酸受容体ならびにＧＡＲＦＴａｓｅおよび／または他の葉酸代謝酵素のインヒビター化合物、ならびにその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110082158A1 (enExample) |
| EP (1) | EP2627332A4 (enExample) |
| JP (1) | JP2014504258A (enExample) |
| CA (1) | CA2813743C (enExample) |
| WO (1) | WO2012051105A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017537107A (ja) * | 2014-12-02 | 2017-12-14 | イーライ リリー アンド カンパニー | １−オキソ−１，２−ジヒドロイソキノリン−７−イル−（５−置換−チオフェン−２−イル）−スルホンアミド化合物、それらの化合物を含む製剤、がん治療におけるａｉｃａｒｆｔ阻害剤としてのそれらの使用 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016089879A1 (en) * | 2014-12-01 | 2016-06-09 | Endocyte, Inc. | Conjugates of garftase inhibitors |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| JP2018504430A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン |
| JP2018504432A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ７阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン |
| WO2016126929A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028608A (en) * | 1989-12-11 | 1991-07-02 | The Trustees Of Princeton University | N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives |
| JPH03173890A (ja) * | 1989-09-21 | 1991-07-29 | Takeda Chem Ind Ltd | ピロロ［２，３―ｄ］ピリミジン誘導体，その製造法，用途及び中間体 |
| JPH04117381A (ja) * | 1989-12-20 | 1992-04-17 | Takeda Chem Ind Ltd | 縮合複素環化合物，その製造法，用途及び中間体 |
| JPH0578362A (ja) * | 1990-01-16 | 1993-03-30 | Takeda Chem Ind Ltd | 縮合複素環化合物，その製造法，用途及び中間体 |
| JPH05186437A (ja) * | 1991-08-21 | 1993-07-27 | Eisai Co Ltd | 縮合ピリミジン誘導体 |
| US5248775A (en) * | 1989-12-11 | 1993-09-28 | The Trustees Of Princeton University | Pyrrolo(2,3-d)pyrimidines |
| JPH06172358A (ja) * | 1991-12-27 | 1994-06-21 | Takeda Chem Ind Ltd | 縮合ピリミジン誘導体、その製造法および用途 |
| JP2000516961A (ja) * | 1996-08-30 | 2000-12-19 | イーライ・リリー・アンド・カンパニー | 非古典的ピロロ［２，３―ｄ］ピリミジン抗葉酸物質 |
| CN101195625A (zh) * | 2007-12-06 | 2008-06-11 | 上海交通大学 | 用于抗肿瘤药物抗叶酸剂及其盐和中间体 |
| US20100081676A1 (en) * | 2008-10-01 | 2010-04-01 | Aleem Gangjee | Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6355190A (en) * | 1989-06-13 | 1991-01-17 | Smithkline Beecham Corporation | Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages |
| EP0438261A3 (en) * | 1990-01-16 | 1992-02-26 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic glutamic acid derivatives, their production and use |
| US5939420A (en) * | 1991-04-08 | 1999-08-17 | Duquesne University Of The Holy Ghost | Pyrrolo 2,3d!derivatives |
| DK1109560T3 (da) * | 1998-09-04 | 2003-11-03 | Agouron Pharma | Som AICARFT-inhibitorer anvendelige forbindelser |
| WO2003020719A1 (en) * | 2001-09-03 | 2003-03-13 | Takeda Chemical Industries, Ltd. | 1,3-benzothiazinone derivatives and use thereof |
| WO2004012769A1 (en) * | 2002-08-02 | 2004-02-12 | The Regents Of The University Of California | Therapeutic inhibitionof protein kinases in cancer cells |
| US20050187389A1 (en) * | 2004-01-13 | 2005-08-25 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| US8030319B2 (en) * | 2005-02-10 | 2011-10-04 | Duquesne University Of The Holy Ghost | Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2 3-d]pyrimidines |
-
2010
- 2010-10-12 US US12/902,310 patent/US20110082158A1/en not_active Abandoned
-
2011
- 2011-10-10 EP EP11833198.2A patent/EP2627332A4/en not_active Withdrawn
- 2011-10-10 JP JP2013533912A patent/JP2014504258A/ja active Pending
- 2011-10-10 CA CA2813743A patent/CA2813743C/en active Active
- 2011-10-10 WO PCT/US2011/055584 patent/WO2012051105A2/en not_active Ceased
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03173890A (ja) * | 1989-09-21 | 1991-07-29 | Takeda Chem Ind Ltd | ピロロ［２，３―ｄ］ピリミジン誘導体，その製造法，用途及び中間体 |
| US5028608A (en) * | 1989-12-11 | 1991-07-02 | The Trustees Of Princeton University | N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives |
| US5248775A (en) * | 1989-12-11 | 1993-09-28 | The Trustees Of Princeton University | Pyrrolo(2,3-d)pyrimidines |
| JPH04117381A (ja) * | 1989-12-20 | 1992-04-17 | Takeda Chem Ind Ltd | 縮合複素環化合物，その製造法，用途及び中間体 |
| JPH0578362A (ja) * | 1990-01-16 | 1993-03-30 | Takeda Chem Ind Ltd | 縮合複素環化合物，その製造法，用途及び中間体 |
| JPH05186437A (ja) * | 1991-08-21 | 1993-07-27 | Eisai Co Ltd | 縮合ピリミジン誘導体 |
| JPH06172358A (ja) * | 1991-12-27 | 1994-06-21 | Takeda Chem Ind Ltd | 縮合ピリミジン誘導体、その製造法および用途 |
| JP2000516961A (ja) * | 1996-08-30 | 2000-12-19 | イーライ・リリー・アンド・カンパニー | 非古典的ピロロ［２，３―ｄ］ピリミジン抗葉酸物質 |
| CN101195625A (zh) * | 2007-12-06 | 2008-06-11 | 上海交通大学 | 用于抗肿瘤药物抗叶酸剂及其盐和中间体 |
| US20100081676A1 (en) * | 2008-10-01 | 2010-04-01 | Aleem Gangjee | Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same |
Non-Patent Citations (2)
| Title |
|---|
| JPN6015031573; Ｐａｒｅｎｔｉ， Ｍａｒｃｏ Ｄａｎｉｅｌｅ ｅｔ ａｌ．: 'Ｔｈｒｅｅ-Ｄｉｍｅｎｓｉｏｎａｌ Ｑｕａｎｔｉｔａｔｉｖｅ Ｓｔｒｕｃｔｕｒｅ-Ａｃｔｉｖｉｔｙ Ｒｅｌａｔｉｏｎｓｈｉｐ Ａｎａｌｙｓｉｓ ｏｆ ａ Ｓｅｔ ｏｆ Ｐｌａｓｍｏｄｉｕｍ ｆａｌｃｉ' Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ ４７（１７）, 2004, ４２５８-４２６７ * |
| JPN6015031574; Ｋｏｔａｋｅ， Ｈｏｓｈｉｈｉｋｏ ｅｔ ａｌ．: 'Ｎｏｖｅｌ ６-５ ｆｕｓｅｄ ｒｉｎｇ ｈｅｔｅｒｏｃｙｃｌｅ ａｎｔｉｆｏｌａｔｅｓ ｗｉｔｈ ｐｏｔｅｎｔ ａｎｔｉｔｕｍｏｒ ａｃｔｉｖｉｔｙ： ｂｒｉｄｇｅ ｍｏｄｉｆｉｃａｔｉｏｎｓ ａｎ' Ｃｈｅｍｉｃａｌ ＆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ ４３（５）, 1995, ８２９-８４１ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017537107A (ja) * | 2014-12-02 | 2017-12-14 | イーライ リリー アンド カンパニー | １−オキソ−１，２−ジヒドロイソキノリン−７−イル−（５−置換−チオフェン−２−イル）−スルホンアミド化合物、それらの化合物を含む製剤、がん治療におけるａｉｃａｒｆｔ阻害剤としてのそれらの使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012051105A3 (en) | 2013-10-24 |
| EP2627332A2 (en) | 2013-08-21 |
| CA2813743C (en) | 2022-11-08 |
| US20110082158A1 (en) | 2011-04-07 |
| CA2813743A1 (en) | 2012-04-19 |
| WO2012051105A2 (en) | 2012-04-19 |
| EP2627332A4 (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3867251B1 (en) | Kras g12c inhibitors | |
| USRE48731E1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| AU2012327210B2 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| KR100840727B1 (ko) | 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법 | |
| US11053252B2 (en) | Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same | |
| JP2014504258A (ja) | 選択的プロトン共役葉酸輸送体および葉酸受容体ならびにＧＡＲＦＴａｓｅおよび／または他の葉酸代謝酵素のインヒビター化合物、ならびにその使用方法 | |
| EA007254B1 (ru) | Соединения, специфические к аденозиновому а, аи арецептору, и их применение | |
| WO2020027083A1 (ja) | キナゾリン化合物を有効成分とする医薬組成物 | |
| AU2002248151A1 (en) | Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof | |
| TWI546304B (zh) | Protein tyrosine kinase inhibitors and their use | |
| CN107459491A (zh) | 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途 | |
| HK40048861B (en) | Kras g12c inhibitors | |
| HK40048861A (en) | Kras g12c inhibitors | |
| HK1259893A1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| HK1259893B (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141009 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141009 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150611 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150805 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151104 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151211 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160205 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160801 |